Alexander Rudensky is Chairman of the Immunology Program and Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan‐Kettering Cancer Center (MSKCC), an Investigator with the Howard Hughes Medical Institute, and a Tri‐Institutional Professor at MSKCC, the Rockefeller University and Cornell University, and Professor at Gerstner School of Graduate Studies and at Weill‐Cornell Medical School.
Dr. Rudensky received his PhD degree from the Gabrichevsky Research Institute of Epidemiology and Microbiology in Moscow. From 1990-1992, during his postdoctoral training at Yale University School of Medicine with the late Dr. Charles Janeway, when together they made the discovery of characterization of self antigens associated with MHC class II molecules. After completing his training, Dr. Rudensky started his independent research career at the University of Washington becoming Professor in the Department of Immunology. He remained in Seattle till 2009 before assuming his current position at MSKCC.
Currently, Dr. Rudensky's research is focused on the development of T lymphocytes, whose function is vital to prevent inflammation in diverse biological settings ranging from pregnancy and autoimmunity to cancer and metabolic disease. His laboratory identified the transcription factor Foxp3 as a Treg cell lineage specification factor and revealed a crucial role for these cells as life-long "guardians" of immune homeostasis. This work established a firm genetic footing for the phenomenon of T cell-mediated suppression of immune mediated inflammation and autoimmunity.
Dr. Rudensky is an elected fellow of the National Academy of Sciences. He is a member of numerous advisory and editorial boards including Cell, Immunity, Cancer Research Institute and Damon Cancer Research Foundation. He serves also as an Editor of the Journal of Experimental Medicine. Dr. Rudensky has authored over 150 peer-reviewed publications.